Publications

2025

  • Cerboni N, Szekér B, Dressler R, Wörle M, Eichler R, Jung TA, et al.
    Unraveling the formation of Tb/Pd films by coupled reduction as targets for heavy ion-beam irradiation
    Journal of Alloys and Compounds. 2025; 1010: 176954 (11 pp.). https://doi.org/10.1016/j.jallcom.2024.176954
    DORA PSI
  • Chirindel A, Nicolas GP, Westerbergh F, McDougall L, Schmid DE, Geistlich S, et al.
    First-in-human administration of [161Tb]Tb-SibuDAB and comparative dosimetry with standard [177Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study
    European Journal of Nuclear Medicine and Molecular Imaging. 2025; 52: 1628-1630. https://doi.org/10.1007/s00259-024-07009-w
    DORA PSI
  • Florit A, de Koster EJ, Sassano S, Alic L, Pisano G, van Velden FHP, et al.
    Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiopharmaceuticals and [18F]FDG in gynaecological malignancies: systematic literature review and meta-analysis
    European Journal of Nuclear Medicine and Molecular Imaging. 2025. https://doi.org/10.1007/s00259-025-07277-0
    DORA PSI
  • Mapanao AK, Busslinger SD, Mehta A, Kegler K, Favaretto C, Grundler PV, et al.
    Preclinical investigation of [149Tb]Tb-DOTATATE and [149Tb]Tb-DOTA-LM3 for tumor-targeted alpha therapy
    European Journal of Nuclear Medicine and Molecular Imaging. 2025; 52: 1383-1398. https://doi.org/10.1007/s00259-024-07035-8
    DORA PSI
  • Mendes F, Terry SYA, Spiegelberg D, Cornelissen B, Bolcaen J, Nonnekens J
    Recommendations for reporting preclinical radiobiological studies in targeted radionuclide therapy
    European Journal of Nuclear Medicine and Molecular Imaging. 2025. https://doi.org/10.1007/s00259-025-07152-y
    DORA PSI
  • Quérel E, Biswas S, Heiss MW, Gerchow L, Wang Q, Asakura R, et al.
    Overcoming the probing-depth dilemma in spectroscopic analyses of batteries with muon-induced X-ray emission (MIXE)
    Journal of Materials Chemistry A. 2025; 13(3): 2275 (10 pp.). https://doi.org/10.1039/d4ta05112b
    DORA PSI
  • Ritt P, Fernández R, Soza-Ried C, Nicolai H, Amaral H, Krieger K, et al.
    Biodistribution and dosimetry of [177Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer
    European Journal of Nuclear Medicine and Molecular Imaging. 2025. https://doi.org/10.1007/s00259-025-07102-8
    DORA PSI
  • Wallimann RH, Mehta A, Mapanao AK, Köster U, Kneuer R, Schindler P, et al.
    Preclinical comparison of (radio)lanthanides using mass spectrometry and nuclear imaging techniques: biodistribution of lanthanide-based tumor-targeting agents and lanthanides in ionic form
    European Journal of Nuclear Medicine and Molecular Imaging. 2025; 52: 1370-1382. https://doi.org/10.1007/s00259-024-07018-9
    DORA PSI
  • Wehrmüller JE, Frei JC, Hechler T, Kulke M, Pahl A, Béhé M, et al.
    Site-specific modification of native IgGs with flexible drug-load
    ChemBioChem. 2025; 26(8): e202400511 (6 pp.). https://doi.org/10.1002/cbic.202400511
    DORA PSI

2024

  • Corpetti M, Müller C, Beltran H, de Bono J, Theurillat JP
    Prostate-specific membrane antigen–targeted therapies for prostate cancer: towards improving therapeutic outcomes
    European Urology. 2024; 85(3): 193-204. https://doi.org/10.1016/j.eururo.2023.11.018
    DORA PSI
  • Favaretto C, Grundler PV, Talip Z, Köster U, Johnston K, Busslinger SD, et al.
    Terbium-149 production: a focus on yield and quality improvement towards preclinical application
    Scientific Reports. 2024; 14(1): 3284 (12 pp.). https://doi.org/10.1038/s41598-024-53610-2
    DORA PSI
  • Fricke J, Westerbergh F, McDougall L, Favaretto C, Christ E, Nicolas GP, et al.
    First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum
    European Journal of Nuclear Medicine and Molecular Imaging. 2024; 51: 2517-2519. https://doi.org/10.1007/s00259-024-06641-w
    DORA PSI
  • Gomes CV, Mendes BM, Paixão L, Gnesin S, Müller C, van der Meulen NP, et al.
    Comparison of the dosimetry of scandium-43 and scandium-44 patient organ doses in relation to commonly used gallium-68 for imaging neuroendocrine tumours
    EJNMMI Physics. 2024; 11(1): 61 (14 pp.). https://doi.org/10.1186/s40658-024-00669-5
    DORA PSI
  • Gutmann M, Reinhardt D, Seidensticker C, Raschig M, Hahn L, Moscaroli A, et al.
    Matrix metalloproteinase-responsive delivery of PEGylated fibroblast growth factor 2
    ACS Biomaterials Science & Engineering. 2024; 10(1): 156-165. https://doi.org/10.1021/acsbiomaterials.3c01511
    DORA PSI
  • Holzleitner N, Cwojdzinski T, Beck R, Urtz-Urban N, Hillhouse CC, Grundler PV, et al.
    Preclinical evaluation of gastrin-releasing peptide receptor antagonists labeled with 161Tb and 177Lu: a comparative study
    Journal of Nuclear Medicine. 2024; 65(3): 481-484. https://doi.org/10.2967/jnumed.123.266233
    DORA PSI
  • Mizuno R, Niikura M, Saito TY, Matsuzaki T, Sakurai H, Amato A, et al.
    Development of wide range photon detection system for muonic X-ray spectroscopy
    Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment. 2024; 1060: 169029 (14 pp.). https://doi.org/10.1016/j.nima.2023.169029
    DORA PSI
  • Moiseeva AN, Favaretto C, Talip Z, Grundler PV, van der Meulen NP
    Terbium sisters: current development status and upscaling opportunities
    Frontiers in Nuclear Medicine. 2024; 4: 1472500 (14 pp.). https://doi.org/10.3389/fnume.2024.1472500
    DORA PSI
  • Müller C, van der Meulen NP
    Terbium "Sisters": more than just a "Swiss Army Knife"
    In: Prasad V, ed. Beyond becquerel and biology to precision radiomolecular oncology: festschrift in honor of Richard P. Baum. Cham: Springer; 2024:225-236. https://doi.org/10.1007/978-3-031-33533-4_23
    DORA PSI
  • Rottenburger C, Hentschel M, Fürstner M, McDougall L, Kottoros D, Kaul F, et al.
    In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study
    EJNMMI Research. 2024; 14(1): 37 (13 pp.). https://doi.org/10.1186/s13550-024-01101-w
    DORA PSI
  • Sarogni P, Brindani N, Zamborlin A, Gonnelli A, Menicagli M, Mapanao AK, et al.
    Tumor growth-arrest effect of tetrahydroquinazoline-derivative human topoisomerase II-alpha inhibitor in HPV-negative head and neck squamous cell carcinoma
    Scientific Reports. 2024; 14(1): 9150 (10 pp.). https://doi.org/10.1038/s41598-024-59592-5
    DORA PSI
  • Scott PJH, Penuelas I, Rey A, Aime S, Ambikalmajan PMR, Antunes IF, et al.
    Highlight selection of radiochemistry and radiopharmacy developments by editorial board
    EJNMMI Radiopharmacy and Chemistry. 2024; 9: 67 (20 pp.). https://doi.org/10.1186/s41181-024-00296-6
    DORA PSI
  • Song Y, Zou J, Castellanos EA, Matsuura N, Ronald JA, Shuhendler A, et al.
    Theranostics - a sure cure for cancer after 100 years?
    Theranostics. 2024; 14(6): 2464-2488. https://doi.org/10.7150/thno.96675
    DORA PSI
  • Tagliente G, Milazzo PM, Paradela C, Kopecky S, Vescovi D, Alaerts G, et al.
    High-resolution cross section measurements for neutron interactions on 89Y with incident neutron energies up to 95 keV
    European Physical Journal A: Hadrons and Nuclei. 2024; 60(1): 21 (18 pp.). https://doi.org/10.1140/epja/s10050-024-01243-4
    DORA PSI
  • Todorov TZ, Schibli R, Béhé M, Grünberg J
    Targeting cancer stem cells with radioimmunotherapy: the case of the ovarian cancer stemness-associated biomarker L1CAM
    International Journal of Translational Medicine. 2024; 4(3): 463-485. https://doi.org/10.3390/ijtm4030031
    DORA PSI
  • Trachsel B, Imobersteg S, Valpreda G, Singer G, Grabherr R, Ormos M, et al.
    Relaxed fibronectin: a potential novel target for imaging endometriotic lesions
    EJNMMI Research. 2024; 14(1): 17 (11 pp.). https://doi.org/10.1186/s13550-024-01070-0
    DORA PSI
  • Vaccarin C, Mapanao AK, Deberle LM, Becker AE, Borgna F, Marzaro G, et al.
    Design and preclinical evaluation of a novel prostate-specific membrane antigen radioligand modified with a transthyretin binder
    Cancers. 2024; 16(7): 1262 (13 pp.). https://doi.org/10.3390/cancers16071262
    DORA PSI
  • Vaccarin C, Veit G, Hegedus T, Torres O, Chilin A, Lukacs GL, et al.
    Synthesis and biological evaluation of pyrazole-pyrimidones as a new class of correctors of the cystic fibrosis transmembrane conductance regulator (CFTR)
    Journal of Medicinal Chemistry. 2024; 67: 13891-13908. https://doi.org/10.1021/acs.jmedchem.4c00685
    DORA PSI
  • Wallimann RH, Hensinger H, Müller C, Schibli R, Kneuer R, Schindler P
    Liquid chromatography ICP-MS to assess the stability of 175Lu- and natGa-based tumor-targeting agents towards the development of 177Lu- and 68Ga-labeled radiopharmaceuticals
    Pharmaceutics. 2024; 16(3): 299 (13 pp.). https://doi.org/10.3390/pharmaceutics16030299
    DORA PSI
  • de Roode KE, Joosten L, Behe M
    Towards the magic radioactive bullet: improving targeted radionuclide therapy by reducing the renal retention of radioligands
    Pharmaceuticals. 2024; 17(2): 256 (31 pp.). https://doi.org/10.3390/ph17020256
    DORA PSI

2023

  • Alcayne V, Mendoza E, Cano-Ott D, Kimura A, Aberle O, Amaducci S, et al.
    Results of the 244Cm, 246Cm and 248Cm neutron-induced capture cross sections measurements at EAR1 and EAR2 of the n_TOF facility
    In: Mattoon CM, Vogt R, Escher J, Thompson I, eds. 15th international conference on nuclear data for science and technology (ND2022). Vol. 284. EPJ web conferences. Les Ulis Cedex A: EDP Sciences; 2023:01009 (6 pp.). https://doi.org/10.1051/epjconf/202328401009
    DORA PSI
  • Beyer D, Vaccarin C, Deupi X, Mapanao AK, Cohrs S, Sozzi-Guo F, et al.
    A tool for nuclear imaging of the SARS-CoV-2 entry receptor: molecular model and preclinical development of ACE2-selective radiopeptides
    EJNMMI Research. 2023; 13(1): 32 (14 pp.). https://doi.org/10.1186/s13550-023-00979-2
    DORA PSI
  • Biswas S, Megatli-Niebel I, Raselli L, Simke R, Cocolios TE, Deokar N, et al.
    The non-destructive investigation of a late antique knob bow fibula (Bügelknopffibel) from Kaiseraugst/CH using Muon Induced X-ray Emission (MIXE)
    Heritage Science. 2023; 11: 43 (17 pp.). https://doi.org/10.1186/s40494-023-00880-0
    DORA PSI
  • Busslinger SD, Becker AE, Vaccarin C, Deberle LM, Renz M-L, Groehn V, et al.
    Investigations using albumin binders to modify the tissue distribution profile of radiopharmaceuticals exemplified with folate radioconjugates
    Cancers. 2023; 15(17): 4259 (19 pp.). https://doi.org/10.3390/cancers15174259
    DORA PSI
  • Chen K, Mackiewicz A, Virtanen S, Grundler PV, Seifert H-P, Ritter S
    Effect of zinc injection on mitigating stress corrosion cracking initiation of structural materials in light water reactor primary water
    Corrosion Reviews. 2023; 41(3): 387-398. https://doi.org/10.1515/corrrev-2022-0098
    DORA PSI
  • Chiera NM, Dressler R, Sprung P, Talip Z, Schumann D
    Determination of the half-life of gadolinium-148
    Applied Radiation and Isotopes. 2023; 194: 110708 (5 pp.). https://doi.org/10.1016/j.apradiso.2023.110708
    DORA PSI
  • Dellepiane G, Casolaro P, Favaretto C, Gottstein A, Grundler PV, Mateu I, et al.
    Cross-section measurement of thulium radioisotopes with an 18 MeV medical PET cyclotron for an optimized 165Er production
    Applied Radiation and Isotopes. 2023; 200: 110954 (11 pp.). https://doi.org/10.1016/j.apradiso.2023.110954
    DORA PSI
  • Ermini ML, Summa M, Zamborlin A, Frusca V, Mapanao AK, Mugnaioli E, et al.
    Copper nano-architecture topical cream for the accelerated recovery of burnt skin
    Nanoscale Advances. 2023; 5(4): 1212-1219. https://doi.org/10.1039/d2na00786j
    DORA PSI
  • Favaretto C, Grundler PV, Talip Z, Landolt S, Sepini L, Köster U, et al.
    161Tb-DOTATOC production using a fully automated disposable cassette system: a first step toward the introduction of 161Tb into the clinic
    Journal of Nuclear Medicine. 2023; 64(7): 1138-1144. https://doi.org/10.2967/jnumed.122.265268
    DORA PSI
  • Grzmil M, Wiesmann F, Schibli R, Behe M
    Targeting mTORC1 activity to improve efficacy of radioligand therapy in cancer
    Cancers. 2023; 15(1): 17 (12 pp.). https://doi.org/10.3390/cancers15010017
    DORA PSI
  • Happl B, Brandt M, Balber T, Benčurová K, Talip Z, Voegele A, et al.
    Synthesis and preclinical evaluation of radiolabeled [103Ru]BOLD-100
    Pharmaceutics. 2023; 15(11): 2626 (11 pp.). https://doi.org/10.3390/pharmaceutics15112626
    DORA PSI
  • Hofmann BA, Bolliger Schreyer S, Biswas S, Gerchow L, Wiebe D, Schumann M, et al.
    An arrowhead made of meteoritic iron from the late Bronze Age settlement of Mörigen, Switzerland and its possible source
    Journal of Archaeological Science. 2023; 157: 105827 (10 pp.). https://doi.org/10.1016/j.jas.2023.105827
    DORA PSI
  • Juget F, Durán T, Nedjadi Y, Talip Z, Grundler PV, Favaretto C, et al.
    Activity measurement of 44Sc and calibration of activity measurement instruments on production sites and clinics
    Molecules. 2023; 28(3): 1345 (10 pp.). https://doi.org/10.3390/molecules28031345
    DORA PSI
  • Kiss OC, Scott PJH, Behe M, Penuelas I, Passchier J, Rey A, et al.
    Highlight selection of radiochemistry and radiopharmacy developments by editorial board
    EJNMMI Radiopharmacy and Chemistry. 2023; 8(1): 6 (18 pp.). https://doi.org/10.1186/s41181-023-00192-5
    DORA PSI
  • Müller C, van der Meulen NP, Schibli R
    Opportunities and potential challenges of using terbium-161 for targeted radionuclide therapy in clinics
    European Journal of Nuclear Medicine and Molecular Imaging. 2023; 50: 3181-3184. https://doi.org/10.1007/s00259-023-06316-y
    DORA PSI
  • Pekeč T, Venkatachalapathy S, Shim AR, Paysan D, Grzmil M, Schibli R, et al.
    Detecting radio- and chemoresistant cells in 3D cancer co-cultures using chromatin biomarkers
    Scientific Reports. 2023; 13(1): 20662 (14 pp.). https://doi.org/10.1038/s41598-023-47287-2
    DORA PSI
  • Qin Y, Imobersteg S, Frank S, Blanc A, Chiorazzo T, Berger P, et al.
    Signaling network response to α-particle–targeted therapy with the 225Ac-labeled minigastrin analog 225Ac-PP-F11N reveals the radiosensitizing potential of histone deacetylase inhibitors
    Journal of Nuclear Medicine. 2023; 64(6): 873-879. https://doi.org/10.2967/jnumed.122.264597
    DORA PSI
  • Radzina M, Saule L, Mamis E, Koester U, Cocolios TE, Pajuste E, et al.
    Novel radionuclides for use in nuclear medicine in Europe: where do we stand and where do we go?
    EJNMMI Radiopharmacy and Chemistry. 2023; 8(1): 27 (16 pp.). https://doi.org/10.1186/s41181-023-00211-5
    DORA PSI
  • Renaldin E, Dellepiane G, Braccini S, Sommerhalder A, Zhang H, van der Meulen NP, et al.
    Study of thulium-167 cyclotron production: a potential medically-relevant radionuclide
    Frontiers in Chemistry. 2023; 11: 1288588 (14 pp.). https://doi.org/10.3389/fchem.2023.1288588
    DORA PSI
  • Ritter S, Grundler PV, Rowthu S
    A decade of research on noble metal chemical addition at PSI – lessons learned
    In: International conference on water chemistry in nuclear reactor systems (NPC 2023). France: Sfen; 2023:(12 pp.).
    DORA PSI
  • Sarogni P, Zamborlin A, Mapanao AK, Logghe T, Brancato L, van Zwol E, et al.
    Hyperthermia reduces irradiation-induced tumor repopulation in an in vivo pancreatic carcinoma model
    Advanced Biology. 2023; 7(10): 2200229 (9 pp.). https://doi.org/10.1002/adbi.202200229
    DORA PSI
  • Sosnin NV, Lederer-Woods C, Krtička M, Garg R, Dietz M, Bacak M, et al.
    Measurement of the 77Se (n, γ) cross section up to 200 keV at the n_TOF facility at CERN
    Physical Review C: Nuclear Physics. 2023; 107(6): 065805 (9 pp.). https://doi.org/10.1103/PhysRevC.107.065805
    DORA PSI
  • Torres-Sánchez P, Praena J, Porras I, Sabaté-Gilarte M, Lederer-Woods C, Aberle O, et al.
    Measurement of the 14N(n, p) 14C cross section at the CERN n_TOF facility from subthermal energy to 800 keV
    Physical Review C: Nuclear Physics. 2023; 107(6): 064617 (15 pp.). https://doi.org/10.1103/PhysRevC.107.064617
    DORA PSI
  • Trachsel B, Valpreda G, Lutz A, Schibli R, Mu L, Béhé M
    Reducing kidney uptake of radiolabelled exendin-4 using variants of the renally cleavable linker MVK
    EJNMMI Radiopharmacy and Chemistry. 2023; 8(1): 21 (11 pp.). https://doi.org/10.1186/s41181-023-00206-2
    DORA PSI
  • Tschan VJ, Busslinger SD, Bernhardt P, Grundler PV, Zeevaart JR, Köster U, et al.
    Albumin-binding and conventional PSMA ligands in combination with 161Tb: biodistribution, dosimetry, and preclinical therapy
    Journal of Nuclear Medicine. 2023; 64(10): 1625-1631. https://doi.org/10.2967/jnumed.123.265524
    DORA PSI
  • Wallimann RH, Schindler P, Hensinger H, Tschan VJ, Busslinger SD, Kneuer R, et al.
    Inductively coupled plasma mass spectrometry - a valid method for the characterization of metal conjugates in view of the development of radiopharmaceuticals
    Molecular Pharmaceutics. 2023; 20(4): 2150-2158. https://doi.org/10.1021/acs.molpharmaceut.2c01092
    DORA PSI

2022

  • Benešová M, Guzik P, Deberle LM, Busslinger SD, Landolt T, Schibli R, et al.
    Design and evaluation of novel albumin-binding folate radioconjugates: systematic approach of varying the linker entities
    Molecular Pharmaceutics. 2022; 19: 963-973. https://doi.org/10.1021/acs.molpharmaceut.1c00932
    DORA PSI
  • Borgna F, Haller S, Monné Rodriguez JM, Ginj M, Grundler PV, Zeevaart JR, et al.
    Combination of terbium-161 with somatostatin receptor antagonists - a potential paradigm shift for the treatment of neuroendocrine neoplasms
    European Journal of Nuclear Medicine and Molecular Imaging. 2022; 49: 1113-1126. https://doi.org/10.1007/s00259-021-05564-0
    DORA PSI
  • Borgna F, Deberle LM, Busslinger SD, Tschan VJ, Walde LM, Becker AE, et al.
    Preclinical investigations to explore the difference between the diastereomers [177Lu]Lu-SibuDAB and [177Lu]Lu-RibuDAB toward prostate cancer therapy
    Molecular Pharmaceutics. 2022; 19(7): 2105-2114. https://doi.org/10.1021/acs.molpharmaceut.1c00994
    DORA PSI
  • Braccini S, Carzaniga TS, Dellepiane G, Grundler PV, Scampoli P, van der Meulen NP, et al.
    Optimization of 68Ga production at an 18 MeV medical cyclotron with solid targets by means of cross-section measurement of 66Ga, 67Ga and 68Ga
    Applied Radiation and Isotopes. 2022; 186: 110252 (9 pp.). https://doi.org/10.1016/j.apradiso.2022.110252
    DORA PSI
  • Busslinger SD, Tschan VJ, Richard OK, Talip Z, Schibli R, Müller C
    [225Ac]Ac-SibuDAB for targeted alpha therapy of prostate cancer: preclinical evaluation and comparison with [225Ac]Ac-PSMA-617
    Cancers. 2022; 14(22): 5651 (16 pp.). https://doi.org/10.3390/cancers14225651
    DORA PSI
  • Che PP, Mapanao AK, Gregori A, Ermini ML, Zamborlin A, Capula M, et al.
    Biodegradable ultrasmall-in-nano architectures loaded with cisplatin prodrug in combination with ionizing radiation induces DNA damage and apoptosis in pancreatic ductal adenocarcinoma
    Cancers. 2022; 14(12): 3034 (17 pp.). https://doi.org/10.3390/cancers14123034
    DORA PSI
  • Chiera NM, Dressler R, Sprung P, Talip Z, Schumann D
    High precision half-life measurement of the extinct radio-lanthanide Dysprosium-154
    Scientific Reports. 2022; 12(1): 8988 (10 pp.). https://doi.org/10.1038/s41598-022-12684-6
    DORA PSI
  • Dellepiane G, Casolaro P, Favaretto C, Grundler PV, Mateu I, Scampoli P, et al.
    Cross section measurement of terbium radioisotopes for an optimized 155Tb production with an 18 MeV medical PET cyclotron
    Applied Radiation and Isotopes. 2022; 184: 110175 (14 pp.). https://doi.org/10.1016/j.apradiso.2022.110175
    DORA PSI
  • Di Liddo R, Verona M, Vaccarin C, Acquasaliente L, Schrenk S, Piccione M, et al.
    Preliminary discovery of small molecule inhibitors of Epidermal Growth Factor Receptor (EGFR) that bind to the extracellular domain
    Cancers. 2022; 14(15): 3647 (22 pp.). https://doi.org/10.3390/cancers14153647
    DORA PSI
  • Durán MT, Juget F, Nedjadi Y, Bailat C, Grundler PV, Talip Z, et al.
    Half-life measurement of 44Sc and 44mSc
    Applied Radiation and Isotopes. 2022; 190: 110507 (10 pp.). https://doi.org/10.1016/j.apradiso.2022.110507
    DORA PSI
  • Eichler R, Kiselev D, Koschik A, Knecht A, van der Meulen N, Scheibl R, et al.
    IMPACT conceptual design report
    Villigen PSI: Paul Scherrer Institut; 2022. PSI Bericht: 22-01.
    DORA PSI
  • Franceschinis E, Roverso M, Gabbia D, De Martin S, Brusegan M, Vaccarin C, et al.
    Self-emulsifying formulations to increase the oral bioavailability of 4,6,4′-trimethylangelicin as a possible treatment for cystic fibrosis
    Pharmaceutics. 2022; 14(9): 1806 (17 pp.). https://doi.org/10.3390/pharmaceutics14091806
    DORA PSI
  • Gillings N, Hjelstuen O, Behe M, Decristoforo C, Elsinga PH, Ferrari V, et al.
    EANM guideline on quality risk management for radiopharmaceuticals
    European Journal of Nuclear Medicine and Molecular Imaging. 2022; 49: 3353-3364. https://doi.org/10.1007/s00259-022-05738-4
    DORA PSI
  • Grzmil M, Boersema P, Sharma A, Blanc A, Imobersteg S, Pruschy M, et al.
    Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)
    Journal of Hematology & Oncology. 2022; 15(1): 123 (5 pp.). https://doi.org/10.1186/s13045-022-01343-y
    DORA PSI
  • Hemmingsson J, Svensson J, van der Meulen NP, Müller C, Bernhardt P
    Active bone marrow S-values for the low-energy electron emitter terbium-161 compared to S-values for lutetium-177 and yttrium-90
    EJNMMI Physics. 2022; 9(1): 65 (13 pp.). https://doi.org/10.1186/s40658-022-00495-7
    DORA PSI
  • Juget F, Talip Z, Nedjadi Y, Durán MT, Grundler PV, Zeevaart JR, et al.
    Precise activity measurements of medical radionuclides using an ionization chamber: a case study with Terbium-161
    EJNMMI Physics. 2022; 9(1): 19 (18 pp.). https://doi.org/10.1186/s40658-022-00448-0
    DORA PSI
  • Miller IS, Khan S, Shiels LP, Das S, O' Farrell AC, Connor K, et al.
    Implementing subtype-specific pre-clinical models of breast cancer to study pre-treatment aspirin effects
    Cancer Medicine. 2022; 11(20): 3820-3836. https://doi.org/10.1002/cam4.4756
    DORA PSI
  • Rigamonti N, Veitonmäki N, Domke C, Barsin S, Jetzer S, Abdelmotaleb O, et al.
    A multispecific anti-CD40 DARPin construct induces tumor-selective CD40 activation and tumor regression
    Cancer Immunology Research. 2022; 10(5): 626-640. https://doi.org/10.1158/2326-6066.CIR-21-0553
    DORA PSI
  • Schmitt J, Schwenck J, Maurer A, Przybille M, Sonanini D, Reischl G, et al.
    Translational immunoPET imaging using a radiolabeled GD2-specific antibody in neuroblastoma
    Theranostics. 2022; 12(13): 5615-5630. https://doi.org/10.7150/thno.56736
    DORA PSI
  • Schwenck J, Maurer A, Beziere N, Fiz F, Boschetti F, Geistlich S, et al.
    Antibody-guided molecular imaging of Aspergillus lung infections in leukemia patients
    Journal of Nuclear Medicine. 2022; 63(9): 1450-1451. https://doi.org/10.2967/jnumed.121.263251
    DORA PSI
  • Tosato M, Verona M, Favaretto C, Pometti M, Zanoni G, Scopelliti F, et al.
    Chelation of theranostic copper radioisotopes with S-rich macrocycles: from radiolabelling of copper-64 to in vivo investigation
    Molecules. 2022; 27(13): 4158 (19 pp.). https://doi.org/10.3390/molecules27134158
    DORA PSI
  • Trebosc V, Lucchini V, Narwal M, Wicki B, Gartenmann S, Schellhorn B, et al.
    Targeting virulence regulation to disarm Acinetobacter baumannii pathogenesis
    Virulence. 2022; 13(1): 1868-1883. https://doi.org/10.1080/21505594.2022.2135273
    DORA PSI
  • Tschan VJ, Borgna F, Schibli R, Müller C
    Impact of the mouse model and molar amount of injected ligand on the tissue distribution profile of PSMA radioligands
    European Journal of Nuclear Medicine and Molecular Imaging. 2022; 49: 470-480. https://doi.org/10.1007/s00259-021-05446-5
    DORA PSI
  • Tschan VJ, Borgna F, Busslinger SD, Stirn M, Monné Rodriguez JM, Bernhardt P, et al.
    Preclinical investigations using [177Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer
    European Journal of Nuclear Medicine and Molecular Imaging. 2022; 49: 3639-3650. https://doi.org/10.1007/s00259-022-05837-2
    DORA PSI
  • Tupini C, Chilin A, Rossi A, De Fino I, Bragonzi A, D’Aversa E, et al.
    New TMA (4,6,4′-trimethyl angelicin) analogues as anti-inflammatory agents in the treatment of cystic fibrosis lung disease
    International Journal of Molecular Sciences. 2022; 23(22): 14483 (20 pp.). https://doi.org/10.3390/ijms232214483
    DORA PSI
  • Vaccarin C, Gabbia D, Franceschinis E, De Martin S, Roverso M, Bogialli S, et al.
    Improved trimethylangelicin analogs for cystic fibrosis: design, synthesis and preliminary screening
    International Journal of Molecular Sciences. 2022; 23(19): 11528 (14 pp.). https://doi.org/10.3390/ijms231911528
    DORA PSI
  • Valpreda G, Trachsel B, Vogel V, Schibli R, Mu L, Behe M
    Dual MVK cleavable linkers effectively reduce renal retention of 111In-fibronectin-binding peptides
    Bioorganic and Medicinal Chemistry. 2022; 73: 117040 (11 pp.). https://doi.org/10.1016/j.bmc.2022.117040
    DORA PSI
  • Zippel C, Ermert J, Patt M, Gildehaus FJ, Ross TL, Reischl G, et al.
    Cyclotrons operated for nuclear medicine and radiopharmacy in the German Speaking D-A-CH countries: an update on current status and trends
    Frontiers in Nuclear Medicine. 2022; 2: 850414 (10 pp.). https://doi.org/10.3389/fnume.2022.850414
    DORA PSI

2021

  • Aime S, Al-Qahtani M, Behe M, Bormans G, Carlucci G, DaSilva JN, et al.
    Highlight selection of radiochemistry and radiopharmacy developments by editorial board
    EJNMMI Radiopharmacy and Chemistry. 2021; 6(1): 13 (19 pp.). https://doi.org/10.1186/s41181-021-00128-x
    DORA PSI
  • Al-Qahtani M, Behe M, Bormans G, Carlucci G, Dasilva J, Decristoforo C, et al.
    Highlight selection of radiochemistry and radiopharmacy developments by editorial board (January-June 2020)
    EJNMMI Radiopharmacy and Chemistry. 2021; 6(1): 5 (13 pp.). https://doi.org/10.1186/s41181-020-00118-5
    DORA PSI
  • Baum RP, Singh A, Kulkarni HR, Bernhardt P, Rydén T, Schuchardt C, et al.
    First-in-human application of terbium-161: a feasibility study using 161Tb-DOTATOC
    Journal of Nuclear Medicine. 2021; 62(10): 1391-1397. https://doi.org/10.2967/jnumed.120.258376
    DORA PSI
  • Bernhardt P, Svensson J, Hemmingsson J, van der Meulen NP, Zeevaart JR, Konijnenberg MW, et al.
    Dosimetric analysis of the short-ranged particle emitter 161Tb for radionuclide therapy of metastatic prostate cancer
    Cancers. 2021; 13(9): 2011 (13 pp.). https://doi.org/10.3390/cancers13092011
    DORA PSI
  • Borgna F, Barritt P, Grundler PV, Talip Z, Cohrs S, Zeevaart JR, et al.
    Simultaneous visualization of 161Tb-and 177Lu-labeled somatostatin analogues using dual-isotope SPECT imaging
    Pharmaceutics. 2021; 13(4): 536 (13 pp.). https://doi.org/10.3390/pharmaceutics13040536
    DORA PSI
  • Deberle LM, Benešová M, Becker AE, Ratz M, Guzik P, Schibli R, et al.
    Novel synthetic strategies enable the efficient development of folate conjugates for cancer radiotheranostics
    Bioconjugate Chemistry. 2021; 32(8): 1617-1628. https://doi.org/10.1021/acs.bioconjchem.1c00198
    DORA PSI
  • Duchemin C, Ramos JP, Stora T, Ahmed E, Aubert E, Audouin N, et al.
    CERN-MEDICIS: a review since commissioning in 2017
    Frontiers in Medicine. 2021; 8: 693682 (11 pp.). https://doi.org/10.3389/fmed.2021.693682
    DORA PSI
  • Durán MT, Juget F, Nedjadi Y, Bochud F, Talip Z, van der Meulen NP, et al.
    Ytterbium-175 half-life determination
    Applied Radiation and Isotopes. 2021; 176: 109893 (8 pp.). https://doi.org/10.1016/j.apradiso.2021.109893
    DORA PSI
  • Favaretto C, Talip Z, Borgna F, Grundler PV, Dellepiane G, Sommerhalder A, et al.
    Cyclotron production and radiochemical purification of terbium-155 for SPECT imaging
    EJNMMI Radiopharmacy and Chemistry. 2021; 6: 37 (17 pp.). https://doi.org/10.1186/s41181-021-00153-w
    DORA PSI
  • Früh SM, Matti U, Spycher PR, Rubini M, Lickert S, Schlichthaerle T, et al.
    Site-specifically-labeled antibodies for super-resolution microscopy reveal in situ linkage errors
    ACS Nano. 2021; 15(7): 12161-12170. https://doi.org/10.1021/acsnano.1c03677
    DORA PSI
  • Gillings N, Hjelstuen O, Ballinger J, Behe M, Decristoforo C, Elsinga P, et al.
    Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals
    EJNMMI Radiopharmacy and Chemistry. 2021; 6(1): 8 (22 pp.). https://doi.org/10.1186/s41181-021-00123-2
    DORA PSI
  • Grob NM, Schibli R, Béhé M, Valverde IE, Mindt TL
    1,5-Disubstituted 1,2,3-triazoles as amide bond isosteres yield novel tumor-targeting minigastrin analogs
    ACS Medicinal Chemistry Letters. 2021; 12(4): 585-592. https://doi.org/10.1021/acsmedchemlett.0c00636
    DORA PSI
  • Grob NM, Schibli R, Béhé M, Mindt TL
    Improved tumor-targeting with peptidomimetic analogs of minigastrin177Lu-PP-F11N
    Cancers. 2021; 13(11): 2629 (12 pp.). https://doi.org/10.3390/cancers13112629
    DORA PSI
  • Grzmil M, Imobersteg S, Blanc A, Frank S, Schibli R, Béhé MP
    Therapeutic response of CCKBR-positive tumors to combinatory treatment with everolimus and the radiolabeled minigastrin analogue [177Lu]Lu-PP-F11N
    Pharmaceutics. 2021; 13(12): 2156 (8 pp.). https://doi.org/10.3390/pharmaceutics13122156
    DORA PSI
  • Guzik P, Fang H-Y, Deberle LM, Benešová M, Cohrs S, Boss SD, et al.
    Identification of a PET radiotracer for imaging of the folate receptor-α: a potential tool to select patients for targeted tumor therapy
    Journal of Nuclear Medicine. 2021; 62(10): 1475-1481. https://doi.org/10.2967/jnumed.120.255760
    DORA PSI
  • Guzik P, Benešová M, Ratz M, Monné Rodríguez JM, Deberle LM, Schibli R, et al.
    Preclinical evaluation of 5-methyltetrahydrofolate-based radioconjugates - new perspectives for folate receptor-targeted radionuclide therapy
    European Journal of Nuclear Medicine and Molecular Imaging. 2021; 48: 972-983. https://doi.org/10.1007/s00259-020-04980-y
    DORA PSI
  • Guzik P, Siwowska K, Fang H-Y, Cohrs S, Bernhardt P, Schibli R, et al.
    Promising potential of [177Lu]Lu-DOTA-folate to enhance tumor response to immunotherapy - a preclinical study using a syngeneic breast cancer model
    European Journal of Nuclear Medicine and Molecular Imaging. 2021; 48: 984-994. https://doi.org/10.1007/s00259-020-05054-9
    DORA PSI
  • Haixia X, Oliveira da Silva de Barros A, do Vale Chaves e Mello F, Sozzi-Guo F, Müller C, Gemini-Piperni S, et al.
    Graphene: insights on biological, radiochemical and ecotoxicological aspects
    Journal of Biomedical Nanotechnology. 2021; 17(1): 131-148. https://doi.org/10.1166/jbn.2021.3006
    DORA PSI
  • Heinke R, Chevallay E, Chrysalidis K, Cocolios TE, Duchemin C, Fedosseev VN, et al.
    Efficient production of high specific activity thulium-167 at Paul Scherrer Institute and CERN-MEDICIS
    Frontiers in Medicine. 2021; 8: 712374 (17 pp.). https://doi.org/10.3389/fmed.2021.712374
    DORA PSI
  • Juget F, Talip Z, Buchillier T, Durán MT, Nedjadi Y, Desorgher L, et al.
    Determination of the gamma and X-ray emission intensities of terbium-161
    Applied Radiation and Isotopes. 2021; 174: 109770 (6 pp.). https://doi.org/10.1016/j.apradiso.2021.109770
    DORA PSI
  • Kramer V, Fernández R, Lehnert W, Jiménez-Franco LD, Soza-Ried C, Eppard E, et al.
    Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC
    European Journal of Nuclear Medicine and Molecular Imaging. 2021; 48: 893-903. https://doi.org/10.1007/s00259-020-05022-3
    DORA PSI
  • Lima TVM, Gnesin S, Strobel K, del Sol Pérez M, Roos JE, Müller C, et al.
    Fifty shades of scandium: comparative study of PET capabilities using Sc-43 and Sc-44 with respect to conventional clinical radionuclides
    Diagnostics. 2021; 11(10): 1826 (11 pp.). https://doi.org/10.3390/diagnostics11101826
    DORA PSI
  • Müller C, Schibli R, Bernhardt P, Köster U, van der Meulen NP
    Terbium radionuclides for theranostics
    In: Caplan MJ, ed. Reference module in biomedical sciences. sine loco: Elsevier; 2021:(12 pp.). https://doi.org/10.1016/B978-0-12-822960-6.00076-4
    DORA PSI
  • Romantini N, Alam S, Dobitz S, Spillmann M, De Foresta M, Schibli R, et al.
    Exploring the signaling space of a GPCR using bivalent ligands with a rigid oligoproline backbone
    Proceedings of the National Academy of Sciences of the United States of America PNAS. 2021; 118(48): e2108776118 (8 pp.). https://doi.org/10.1073/pnas.2108776118
    DORA PSI
  • Rowthu S, Grundler PV, Müller E, Ritter S
    Pt catalytic effects on the corrosion and hydrogen chemisorption properties of Zircaloy-2
    Journal of Nuclear Materials. 2021; 544: 152716 (15 pp.). https://doi.org/10.1016/j.jnucmat.2020.152716
    DORA PSI
  • Taddio MF, Castro Jaramillo CA, Runge P, Blanc A, Keller C, Talip Z, et al.
    In vivo imaging of local inflammation: monitoring LPS-induced CD80/CD86 upregulation by PET
    Molecular Imaging and Biology. 2021; 23: 196-207. https://doi.org/10.1007/s11307-020-01543-3
    DORA PSI
  • Talip Z, Juget F, Ulrich J, Nedjadi Y, Buchillier T, Durán MT, et al.
    Determination of the gamma and X-ray emission intensities of erbium-169
    Applied Radiation and Isotopes. 2021; 176: 109823 (9 pp.). https://doi.org/10.1016/j.apradiso.2021.109823
    DORA PSI
  • Talip Z, Borgna F, Müller C, Ulrich J, Duchemin C, Ramos JP, et al.
    Production of mass-separated erbium-169 towards the first preclinical in vitro investigations
    Frontiers in Medicine. 2021; 8: 643175 (11 pp.). https://doi.org/10.3389/fmed.2021.643175
    DORA PSI
  • Talip Z, Dressler R, Schacherl B, David J-C, Vockenhuber C, Schumann D
    Radiochemical determination of long-lived radionuclides in proton-irradiated heavy metal targets: part II tungsten
    Analytical Chemistry. 2021; 93(31): 10798-10806. https://doi.org/10.1021/acs.analchem.1c00640
    DORA PSI
  • Wang H, Lallemang M, Hermann B, Wallin C, Loch R, Blanc A, et al.
    ATP impedes the inhibitory effect of Hsp90 on Aβ40 fibrillation
    Journal of Molecular Biology. 2021; 433(2): 166717 (16 pp.). https://doi.org/10.1016/j.jmb.2020.11.016
    DORA PSI
  • van der Meulen NP, Talip Z
    Non-conventional radionuclides: the pursuit for perfection
    In: Caplan MJ, ed. Reference module in biomedical sciences. sine loco: Elsevier; 2021:(10 pp.). https://doi.org/10.1016/B978-0-12-822960-6.00052-1
    DORA PSI

2020

  • Alcayne V, Mendoza E, Cano-Ott D, Kimura A, Aberle O, Amaducci S, et al.
    Measurement of the 244Cm capture cross sections at both CERN n_TOF experimental areas
    In: Ge Z, Shu N, Chen Y, Wang W, Zhang H, eds. ND 2019: international conference on nuclear data for science and technology. Vol. 239. EPJ web of conferences. Sine loco: EDP Sciences; 2020:01034 (5 pp.). https://doi.org/10.1051/epjconf/202023901034
    DORA PSI
  • Bierig T, Collu G, Blanc A, Poghosyan E, Benoit RM
    Design, expression, purification, and characterization of a YFP-tagged 2019-n CoV spike receptor-binding domain construct
    Frontiers in Bioengineering and Biotechnology. 2020; 8: 618615 (10 pp.). https://doi.org/10.3389/fbioe.2020.618615
    DORA PSI
  • Borgna F, Deberle LM, Cohrs S, Schibli R, Müller C
    Combined application of albumin-binding [177Lu]Lu-PSMA-ALB-56 and fast-cleared PSMA inhibitors: optimization of the pharmacokinetics
    Molecular Pharmaceutics. 2020; 17(6): 2044-2053. https://doi.org/10.1021/acs.molpharmaceut.0c00199
    DORA PSI
  • Chiera NM, Talip Z, Fankhauser A, Schumann D
    Separation and recovery of exotic radiolanthanides from irradiated tantalum targets for half-life measurements
    PLoS One. 2020; 15(7): e0235711 (19 pp.). https://doi.org/10.1371/journal.pone.0235711
    DORA PSI
  • Deberle LM, Tschan VJ, Borgna F, Sozzi-Guo F, Bernhardt P, Schibli R, et al.
    Albumin-binding PSMA radioligands: impact of minimal structural changes on the tissue distribution profile
    Molecules. 2020; 25(11): 2542 (16 pp.). https://doi.org/10.3390/molecules25112542
    DORA PSI
  • Deberle LM, Benešová M, Umbricht CA, Borgna F, Büchler M, Zhernosekov K, et al.
    Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity
    Theranostics. 2020; 10(4): 1678-1693. https://doi.org/10.7150/thno.40482
    DORA PSI
  • Dobitz S, Wilhelm P, Romantini N, De Foresta M, Walther C, Ritler A, et al.
    Distance-dependent cellular uptake of oligoproline-based homobivalent ligands targeting GPCRs - an experimental and computational analysis
    Bioconjugate Chemistry. 2020; 31(10): 2431-2438. https://doi.org/10.1021/acs.bioconjchem.0c00484
    DORA PSI
  • Dodich A, Mendes A, Assal F, Chicherio C, Rakotomiaramanana B, Andryszak P, et al.
    The A/T/N model applied through imaging biomarkers in a memory clinic
    European Journal of Nuclear Medicine and Molecular Imaging. 2020; 47(2): 247-255. https://doi.org/10.1007/s00259-019-04536-9
    DORA PSI
  • Durán MT, Juget F, Nedjadi Y, Bochud F, Grundler PV, Gracheva N, et al.
    Determination of 161Tb half-life by three measurement methods
    Applied Radiation and Isotopes. 2020; 159: 109085 (9 pp.). https://doi.org/10.1016/j.apradiso.2020.109085
    DORA PSI
  • Fonta CM, Arnoldini S, Jaramillo D, Moscaroli A, Oxenius A, Behe M, et al.
    Fibronectin fibers are highly tensed in healthy organs in contrast to tumors and virus-infected lymph nodes
    Matrix Biology Plus. 2020; 8: 100046 (15 pp.). https://doi.org/10.1016/j.mbplus.2020.100046
    DORA PSI
  • Gillings N, Todde S, Behe M, Decristoforo C, Elsinga P, Ferrari V, et al.
    EANM guideline on the validation of analytical methods for radiopharmaceuticals
    EJNMMI Radiopharmacy and Chemistry. 2020; 5(1): 7 (29 pp.). https://doi.org/10.1186/s41181-019-0086-z
    DORA PSI
  • Gnesin S, Müller J, Burger IA, Meisel A, Siano M, Früh M, et al.
    Radiation dosimetry of 18F-AzaFol: a first in-human use of a folate receptor PET tracer
    EJNMMI Research. 2020; 10(1): 32 (12 pp.). https://doi.org/10.1186/s13550-020-00624-2
    DORA PSI
  • Gracheva N, Carzaniga TS, Schibli R, Braccini S, van der Meulen NP
    165Er: a new candidate for Auger electron therapy and its possible cyclotron production from natural holmium targets
    Applied Radiation and Isotopes. 2020; 159: 109079 (8 pp.). https://doi.org/10.1016/j.apradiso.2020.109079
    DORA PSI
  • Grob NM, Schmid S, Schibli R, Behe M, Mindt TL
    Design of radiolabeled analogs of minigastrin by multiple amide-to-triazole substitutions
    Journal of Medicinal Chemistry. 2020; 63(9): 4496-4505. https://doi.org/10.1021/acs.jmedchem.9b01937
    DORA PSI
  • Grob NM, Häussinger D, Deupi X, Schibli R, Behe M, Mindt TL
    Triazolo-peptidomimetics: novel radiolabeled minigastrin analogs for improved tumor targeting
    Journal of Medicinal Chemistry. 2020; 63(9): 4484-4495. https://doi.org/10.1021/acs.jmedchem.9b01936
    DORA PSI
  • Grundler PV, Eichler R, Talip Z, Schubiger PA, Schibli R, van der Meulen NP
    The metamorphosis of radionuclide production and development at Paul Scherrer Institute
    Chimia. 2020; 74(12): 968-975. https://doi.org/10.2533/CHIMIA.2020.968
    DORA PSI
  • Grzmil M, Qin Y, Schleuniger C, Frank S, Imobersteg S, Blanc A, et al.
    Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [177Lu]Lu-PP-F11N
    Theranostics. 2020; 10(24): 10861-10873. https://doi.org/10.7150/thno.45440
    DORA PSI
  • Lima TVM, Gnesin S, Nitzsche E, Ortega PG, Müller C, van der Meulen NP
    First phantom-based quantitative assessment of scandium-44 using a commercial PET device
    Frontiers in Physics. 2020; 8: 241 (10 pp.). https://doi.org/10.3389/fphy.2020.00241
    DORA PSI
  • Lühmann T, Gutmann M, Moscaroli A, Raschig M, Béhé M, Meinel L
    Biodistribution of site-specific PEGylated fibroblast growth factor-2
    ACS Biomaterials Science & Engineering. 2020; 6(1): 425-432. https://doi.org/10.1021/acsbiomaterials.9b01248
    DORA PSI
  • Marin I, Rydèn T, Van Essen M, Svensson J, Gracheva N, Köster U, et al.
    Establishment of a clinical SPECT/CT protocol for imaging of 161Tb
    EJNMMI Physics. 2020; 7(1): 45 (16 pp.). https://doi.org/10.1186/s40658-020-00314-x
    DORA PSI
  • Mazzone A, Cristallo S, Aberle O, Alaerts G, Alcayne V, Amaducci S, et al.
    Measurement of the 154Gd(n,γ) cross section and its astrophysical implications
    Physics Letters, Section B: Nuclear, Elementary Particle and High-Energy Physics. 2020; 804: 135405 (6 pp.). https://doi.org/10.1016/j.physletb.2020.135405
    DORA PSI
  • Mendoza E, Alcayne V, Cano-Ott D, Kimura A, Skarbeli AV, Aberle O, et al.
    Study of photon strength functions of 241Pu and 245Cm from neutron capture measurements
    In: Ge Z, Shu N, Chen Y, Wang W, Zhang H, eds. ND 2019: international conference on nuclear data for science and technology. Vol. 239. EPJ web of conferences. Les Ulis Cedex A: EDP Sciences; 2020:05006 (6 pp.). https://doi.org/10.1051/epjconf/202023901015
    DORA PSI
  • Müller C, Schibli R, Maurer B
    Can nuclear imaging of activated macrophages with folic acid-based radiotracers serve as a prognostic means to identify COVID-19 patients at risk?
    Pharmaceuticals. 2020; 13(9): 238 (8 pp.). https://doi.org/10.3390/ph13090238
    DORA PSI
  • Müller C, Béhé M, Geistlich S, van der Meulen NP, Schibli R
    Targeted radiotherapeutics from 'bench-to-bedside'
    Chimia. 2020; 74(12): 939-945. https://doi.org/10.2533/CHIMIA.2020.939
    DORA PSI
  • Nedjadi Y, Juget F, Desorgher L, Durán MT, Bochud F, Müller C, et al.
    Activity standardisation of 161Tb
    Applied Radiation and Isotopes. 2020; 166: 109411 (13 pp.). https://doi.org/10.1016/j.apradiso.2020.109411
    DORA PSI
  • Nizou G, Favaretto C, Borgna F, Grundler PV, Saffon-Merceron N, Platas-Iglesias C, et al.
    Expanding the scope of pyclen-picolinate lanthanide chelates to potential theranostic applications
    Inorganic Chemistry. 2020; 59(16): 11736-11748. https://doi.org/10.1021/acs.inorgchem.0c01664
    DORA PSI
  • Oprea A, Gunsing F, Schillebeeckx P, Aberle O, Bacak M, Berthoumieux E, et al.
    Neutron capture cross section measurements of 241Am at the n_TOF facility
    In: Ge Z, Shu N, Chen Y, Wang W, Zhang H, eds. ND 2019: international conference on nuclear data for science and technology. Vol. 239. EPJ web of conferences. Les Ulis Cedex A: EDP Sciences; 2020:01009 (5 pp.). https://doi.org/10.1051/epjconf/202023901009
    DORA PSI
  • Pamula F, Mühle J, Blanc A, Nehmé R, Edwards PC, Tate CG, et al.
    Strategic screening and characterization of the visual GPCR-mini-G protein signaling complex for successful crystallization
    Journal of Visualized Experiments. 2020; 2020(157): e60747 (10 pp.). https://doi.org/10.3791/60747
    DORA PSI
  • Pietzsch H-J, Mamat C, Müller C, Schibli R
    Single photon emission computed tomography tracer
    In: Schober O, Kiessling F, Debus J, eds. Molecular imaging in oncology. Recent results in cancer research. Cham: Springer Nature; 2020:227-282. https://doi.org/10.1007/978-3-030-42618-7_7
    DORA PSI
  • Qin Y, Imobersteg S, Blanc A, Frank S, Schibli R, Béhé MP, et al.
    Evaluation of actinium-225 labeled minigastrin analogue [225Ac]Ac-DOTA-PP-F11N for targeted alpha particle therapy
    Pharmaceutics. 2020; 12(11): 1088 (12 pp.). https://doi.org/10.3390/pharmaceutics12111088
    DORA PSI
  • Rottenburger C, Nicolas GP, McDougall L, Kaul F, Cachovan M, Vija AH, et al.
    Cholecystokinin-2 receptor agonist 177Lu-PP-F11N for radionuclide therapy of medullary thyroid carcinoma - results of the lumed phase 0a study
    Journal of Nuclear Medicine. 2020; 61(4): 520-526. https://doi.org/10.2967/jnumed.119.233031
    DORA PSI
  • Spillmann M, Thurner L, Romantini N, Zimmermann M, Meger B, Behe M, et al.
    New insights into arrestin recruitment to GPCRs
    International Journal of Molecular Sciences. 2020; 21(14): 4949 (14 pp.). https://doi.org/10.3390/ijms21144949
    DORA PSI
  • Talip Z, Favaretto C, Geistlich S, van der Meulen NP
    A step-by-step guide for the novel radiometal production for medical applications: case studies with 68Ga, 44Sc, 177Lu and 161Tb
    Molecules. 2020; 25(4): 966 (29 pp.). https://doi.org/10.3390/molecules25040966
    DORA PSI
  • Terraneo N, Jacob F, Peitzsch C, Dubrovska A, Krudewig C, Huang Y-L, et al.
    L1 cell adhesion molecule confers radioresistance to ovarian cancer and defines a new cancer stem cell population
    Cancers. 2020; 12(1): 217 (17 pp.). https://doi.org/10.3390/cancers12010217
    DORA PSI
  • Terraneo N, Jacob F, Dubrovska A, Grünberg J
    Novel therapeutic strategies for ovarian cancer stem cells
    Frontiers in Oncology. 2020; 10: 319 (17 pp.). https://doi.org/10.3389/fonc.2020.00319
    DORA PSI
  • Zhang H, Eichler R, Grillenberger J, Hirzel W, Joray S, Kiselev DC, et al.
    BDSIM simulation of the complete radionuclide production beam line from beam splitter to target station at the PSI cyclotron facility
    In: Conradie L, Garrett De Villiers J, Schaa VRW, eds. CYC2019. 22nd international conference on cyclotrons and their applications. Vol. 22. International conference on cyclotrons and their applications. Geneva: JACoW Publishing; 2020:275-278. https://doi.org/10.18429/JACoW-Cyclotrons2019-WEB04
    DORA PSI
  • van der Meulen NP, Hasler R, Talip Z, Grundler PV, Favaretto C, Umbricht CA, et al.
    Developments toward the implementation of 44Sc production at a medical cyclotron
    Molecules. 2020; 25(20): 4706 (16 pp.). https://doi.org/10.3390/molecules25204706
    DORA PSI
  • van der Meulen NP, Eichler R, Grundler PV, Hasler R, Hirzel W, Joray S, et al.
    The use of PSI's IP2 beam line towards exotic radionuclide development and its application towards proof-of-preclnical and clinical studies
    In: Conradie L, Garrett De Villiers J, Schaa VRW, eds. CYC2019. 22nd international conference on cyclotrons and their applications. Vol. 22. International conference on cyclotrons and their applications. Geneva: JACoW Publishing; 2020:132-135. https://doi.org/10.18429/JACoW-Cyclotrons2019-TUA03
    DORA PSI

2019

  • Alcayne V, Kimura A, Mendoza E, Cano-Ott D, Aberle O, Amaducci S, et al.
    Measurement of the 244Cm and 246Cm neutron-induced cross sections at the n_TOF facility
    In: García-Ramos J-E, Andrés MV, Pérez-Bernal F, Valera JA, Moro AM, eds. Basic concepts in nuclear physics: theory, experiments and applications. 2018 La Rábida international scientific meeting on nuclear physics. Vol. 225. Springer proceedings in physics. Cham: Springer; 2019:117-122. https://doi.org/10.1007/978-3-030-22204-8_4
    DORA PSI
  • Alcayne V, Kimura A, Mendoza E, Cano-Ott D, Martínez T, Aberle O, et al.
    Measurement of the 244Cm and 246Cm neutron-induced capture cross sections at the n_TOF facility
    In: Serot O, Chebboubi A, eds. WONDER-2018 - 5th international workshop on nuclear data evaluation for reactor applications. Vol. 211. EPJ web of conferences. sine loco: EDP Sciences; 2019:03008 (8 pp.). https://doi.org/10.1051/epjconf/201921103008
    DORA PSI
  • Babiano-Suarez V, Caballero L, Domingo-Pardo C, Ladarescu I, Aberle O, Alcayne V, et al.
    Characterization and first test of an i-TED prototype at CERN n_TOF
    In: García-Ramos J-E, Andrés MV, Pérez-Bernal F, Valera JA, Moro AM, eds. Basic concepts in nuclear physics: theory, experiments and applications. 2018 La Rábida international scientific meeting on nuclear physics. Vol. 225. Springer proceedings in physics. Cham: Springer; 2019:169-173. https://doi.org/10.1007/978-3-030-22204-8_18
    DORA PSI
  • Boss SD, Müller C, Siwowska K, Schmid RM, Groehn V, Schibli R, et al.
    Diastereomerically pure 6R- and 6S-3'-aza-2'-18F-fluoro-5-methyltetrahydrofolates show unprecedentedly high uptake in folate receptor-positive KB tumors
    Journal of Nuclear Medicine. 2019; 60(1): 135-141. https://doi.org/10.2967/jnumed.118.213314
    DORA PSI
  • Brandl F, Merten H, Zimmermann M, Béhé M, Zangemeister-Wittke U, Plückthun A
    Influence of size and charge of unstructured polypeptides on pharmacokinetics and biodistribution of targeted fusion proteins
    Journal of Controlled Release. 2019; 307: 379-392. https://doi.org/10.1016/j.jconrel.2019.06.030
    DORA PSI
  • Buitinga M, Jansen T, van der Kroon I, Woliner-van der Weg W, Boss M, Janssen M, et al.
    Succinylated gelatin improves the theranostic potential of radiolabeled exendin-4 in insulinoma patients
    Journal of Nuclear Medicine. 2019; 60(6): 812-816. https://doi.org/10.2967/jnumed.118.219980
    DORA PSI
  • Carzaniga TS, van der Meulen NP, Hasler R, Kottler C, Peier P, Türler A, et al.
    Measurement of the 43Sc production cross-section with a deuteron beam
    Applied Radiation and Isotopes. 2019; 145: 205-208. https://doi.org/10.1016/j.apradiso.2018.12.031
    DORA PSI
  • Cicone F, Gnesin S, Denoël T, Stora T, van der Meulen NP, Müller C, et al.
    Internal radiation dosimetry of a 152Tb-labeled antibody in tumor-bearing mice
    EJNMMI Research. 2019; 9: 53 (10 pp.). https://doi.org/10.1186/s13550-019-0524-7
    DORA PSI
  • Gracheva N, Müller C, Talip Z, Heinitz S, Köster U, Zeevaart JR, et al.
    Production and characterization of no-carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapy
    EJNMMI Radiopharmacy and Chemistry. 2019; 4: 12 (16 pp.). https://doi.org/10.1186/s41181-019-0063-6
    DORA PSI
  • Grzmil M, Meisel A, Behé M, Schibli R
    An overview of targeted radiotherapy
    In: Lewis JS, Windhorst AD, Zeglis BM, eds. Radiopharmaceutical chemistry. Cham: Springer; 2019:85-100. https://doi.org/10.1007/978-3-319-98947-1_5
    DORA PSI
  • Grünberg J, Terraneo N
    L1CAM. Ein vielversprechendes Zellmembranprotein für therapeutische Interventionen
    Lead. Opin. Hämatol. Onkolog. 2019:6-8.
    DORA PSI
  • He Y, Mu L, Ametamey SM, Schibli R
    Recent progress in allosteric modulators for GluN2A subunit and development of GluN2A-selective nuclear imaging probes
    Journal of Labelled Compounds and Radiopharmaceuticals. 2019; 62(8): 552-560. https://doi.org/10.1002/jlcr.3744
    DORA PSI
  • Iacovacci V, Blanc A, Huang H, Ricotti L, Schibli R, Menciassi A, et al.
    High‐resolution SPECT imaging of stimuli‐responsive soft microrobots
    Small. 2019; 15(34): 1900709 (7 pp.). https://doi.org/10.1002/smll.201900709
    DORA PSI
  • Jansen TJP, van Lith SAM, Boss M, Brom M, Joosten L, Béhé M, et al.
    Exendin-4 analogs in insulinoma theranostics
    Journal of Labelled Compounds and Radiopharmaceuticals. 2019; 62(10): 656-672. https://doi.org/10.1002/jlcr.3750
    DORA PSI
  • Kaeppeli SAM, Schibli R, Mindt TL, Behe M
    Comparison of desferrioxamine and NODAGA for the gallium-68 labeling of exendin-4
    EJNMMI Radiopharmacy and Chemistry. 2019; 4(1): 9 (11 pp.). https://doi.org/10.1186/s41181-019-0060-9
    DORA PSI
  • Kaeppeli SAM, Jodal A, Gotthardt M, Schibli R, Behe M
    Exendin-4 derivatives with an albumin-binding moiety show decreased renal retention and improved GLP-1 receptor targeting
    Molecular Pharmaceutics. 2019; 16(9): 3760-3769. https://doi.org/10.1021/acs.molpharmaceut.9b00271
    DORA PSI
  • Kranzbühler B, Salemi S, Umbricht CA, Deberle LM, Müller C, Burger IA, et al.
    Concentration‐dependent effects of dutasteride on prostate‐specific membrane antigen (PSMA) expression and uptake of 177Lu‐PSMA‐617 in LNCaP cells
    Prostate. 2019; 79(12): 1477-1483. https://doi.org/10.1002/pros.23868
    DORA PSI
  • Müller C, De Prado Leal M, Dominietto MD, Umbricht CA, Safai S, Perrin RL, et al.
    Combination of proton therapy and radionuclide therapy in mice: preclinical pilot sudy at the Paul Scherrer Institute
    Pharmaceutics. 2019; 11(9): 450 (13 pp.). https://doi.org/10.3390/pharmaceutics11090450
    DORA PSI
  • Müller C, Singh A, Umbricht CA, Kulkarni HR, Johnston K, Benešová M, et al.
    Preclinical investigations and first-in-human application of 152Tb-PSMA-617 for PET/CT imaging of prostate cancer
    EJNMMI Research. 2019; 9(1): 68 (10 pp.). https://doi.org/10.1186/s13550-019-0538-1
    DORA PSI
  • Müller C, Umbricht CA, Gracheva N, Tschan VJ, Pellegrini G, Bernhardt P, et al.
    Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer
    European Journal of Nuclear Medicine and Molecular Imaging. 2019; 46(9): 1919-1930. https://doi.org/10.1007/s00259-019-04345-0
    DORA PSI
  • Pretze M, van der Meulen N P, Wängler C, Schibli R, Wängler B
    Targeted 64Cu-labeled gold nanoparticles for dual imaging with positron emission tomography and optical imaging
    Journal of Labelled Compounds and Radiopharmaceuticals. 2019; 62(8): 471-482. https://doi.org/10.1002/jlcr.3736
    DORA PSI
  • Radford LL, Fernandez S, Beacham R, Sayed RE, Farkas R, Benešová M, et al.
    New 55Co-labeled albumin-binding folate derivatives as potential PET agents for folate receptor imaging
    Pharmaceuticals. 2019; 12(4): 166 (12 pp.). https://doi.org/10.3390/ph12040166
    DORA PSI
  • Ritler A, Shoshan MS, Deupi X, Wilhelm P, Schibli R, Wennemers H, et al.
    Elucidating the structure−activity relationship of the pentaglutamic acid sequence of minigastrin with cholecystokinin receptor subtype 2
    Bioconjugate Chemistry. 2019; 30(3): 657-666. https://doi.org/10.1021/acs.bioconjchem.8b00849
    DORA PSI
  • Ritter S, Grundler PV, Rowthu S
    Assessment of the SCC mitigation capabilities of the NobleChemTM technology in simulated BWR environment
    Presented at: ICG-EAC Annual Meeting 2019; May 12-17, 2019; Tainan, Taiwan.
    DORA PSI
  • Rowthu S, Yeh Y-W, Grundler PV, Holmes R, Ritter S
    Assessment of the Pt nanoparticle distribution on oxidized stainless steel surfaces by electrochemical techniques
    Presented at: EUROCORR 2019; September 9-13, 2019; Seville, Spain.
    DORA PSI
  • Rupp NJ, Umbricht CA, Pizzuto DA, Lenggenhager D, Töpfer A, Müller J, et al.
    First clinico-pathological evidence of a non PSMA-related uptake mechanism for 68Ga-PSMA-11 in salivary glands
    Journal of Nuclear Medicine. 2019; 60(9): 1270-1276. https://doi.org/10.2967/jnumed.118.222307
    DORA PSI
  • Sauter AW, Mansi R, Hassiepen U, Muller L, Panigada T, Wiehr S, et al.
    Targeting of the cholecystokinin-2 receptor with the minigastrin analog 177Lu-DOTA-PP-F11N: does the use of protease inhibitors further improve in vivo distribution?
    Journal of Nuclear Medicine. 2019; 60(3): 393-399. https://doi.org/10.2967/jnumed.118.207845
    DORA PSI
  • Schniering J, Benešová M, Brunner M, Haller S, Cohrs S, Frauenfelder T, et al.
    18F-AzaFol for detection of folate receptor-β positive macrophages in experimental interstitial lung disease - a proof-of-concept study
    Frontiers in Immunology. 2019; 10: 2724 (15 pp.). https://doi.org/10.3389/fimmu.2019.02724
    DORA PSI
  • Schniering J, Benešová M, Brunner M, Haller S, Cohrs S, Frauenfelder T, et al.
    Visualisation of interstitial lung disease by molecular imaging of integrin αvβ3 and somatostatin receptor 2
    Annals of the Rheumatic Diseases. 2019; 78(2): 218-227. https://doi.org/10.1136/annrheumdis-2018-214322
    DORA PSI
  • Siwowska K, Guzik P, Domnanich KA, Monné Rodríguez JM, Bernhardt P, Ponsard B, et al.
    Therapeutic potential of 47Sc in comparison to 177Lu and 90Y: preclinical investigations
    Pharmaceutics. 2019; 11(8): 424 (13 pp.). https://doi.org/10.3390/pharmaceutics11080424
    DORA PSI
  • Umbricht CA, Köster U, Bernhardt P, Gracheva N, Johnston K, Schibli R, et al.
    Alpha-PET for prostate cancer: preclinical investigation using 149Tb-PSMA-617
    Scientific Reports. 2019; 9: 17800 (10 pp.). https://doi.org/10.1038/s41598-019-54150-w
    DORA PSI
  • Zhang J, Singh A, Kulkarni HR, Schuchardt C, Müller D, Wester H-J, et al.
    From bench to bedside—the Bad Berka experience with first-in-human studies
    Seminars in Nuclear Medicine. 2019; 49(5): 422-437. https://doi.org/10.1053/j.semnuclmed.2019.06.002
    DORA PSI
  • van der Meulen NP, Hasler R, Blanc A, Farkas R, Benešová M, Talip Z, et al.
    Implementation of a new separation method to produce qualitatively improved 64Cu
    Journal of Labelled Compounds and Radiopharmaceuticals. 2019; 62(8): 460-470. https://doi.org/10.1002/jlcr.3730
    DORA PSI

2018

  • Visualisation of interstitial lung disease by molecular imaging of integrin αvβ3 and somatostatin receptor 2 Schniering J, Benešová M, Brunner M, Haller S, Cohrs S, Frauenfelder T, Vrugt B, Feghali-Bostwick CA, Schibli R, Distler O, Mueller C, Maurer B
    ANNALS OF THE RHEUMATIC DISEASES , (2018).
    DOI: annrheumdis-2018-214322
  • Design and Preclinical Evaluation of an Albumin-Binding PSMA Ligand for 64Cu-Based PET Imaging Umbricht CA, Benešová M, Hasler R, Schibli R, van der Meulen NP, Müller C
    MOLECULAR PHARMACEUTICS , (2018).
    DOI: acs.molpharmaceut.8b00712
  • Metabotropic glutamate receptor subtype 5 is altered in LPS-induced murine neuroinflammation model and in the brains of AD and ALS patients Müller Herde A, Schibli R, Weber M, Ametamey SM
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , (2018).
    DOI: s00259-018-4179-9
  • In Vivo Labeling of Plasma Proteins for Imaging of Enhanced Vascular Permeability in the Lungs Schniering J, Borgna F, Siwowska K, Benešová M, Cohrs S, Hasler R, van der Meulen NP, Maurer B, Schibli R, Müller C
    MOLECULAR PHARMACEUTICS 15, 4995 (2018).
    DOI: acs.molpharmaceut.8b00606
  • Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma Lindenblatt D, Terraneo N, Pellegrini G, Cohrs S, Spycher PR, Vukovic D, Béhé M, Schibli R, Grünberg J
    BMC CANCER 18, 922 (2018).
    DOI: s12885-018-4836-1
  • Ketamine and Ceftriaxone-Induced Alterations in Glutamate Levels Do Not Impact the Specific Binding of Metabotropic Glutamate Receptor Subtype 5 Radioligand [18F]PSS232 in the Rat Brain Müller Herde A, Boss SD, He Y, Schibli R, Mu L, Ametamey SM
    PHARMACEUTICASL (BASEL) E83, (2018).
    DOI: ph11030083
  • Evaluation of 99mTc-rhAnnexin V-128 SPECT/CT as a diagnostic tool for early stages of interstitial lung disease associated with systemic sclerosis Schniering J, Guo L, Brunner M, Schibli R, Ye S, Distler O, Béhé M, Maurer B
    ATHRITIS RESEARCH AND THERAPY 20, 183 (2018).
    DOI: s13075-018-1681-1
  • Identification and Preclinical Evaluation of a Radiofluorinated Benzazepine Derivative for Imaging the GluN2B Subunit of the Ionotropic NMDA Receptor Haider A, Iten I, Ahmed H, Müller Herder A, Gruber S, Krämer SD, Keller C, Schibli R, Wünsch B, Mu L, Ametamey SM
    JOURNAL OF NUCLEAR MEDICINE , (2018).
    DOI: jnumed.118.212134
  • Physiologically Based Pharmacokinetic Modelling with Dynamic PET Data to Study the In Vivo Effects of Transporter Inhibition on Hepatobiliary Clearance in Mice Taddio MF, Mu L, Keller C, Schibli R, Krämer SD
    CONTRAST MEDIA AND MOLECULAR IMAGING 5849047, (2018).
    DOI: 5849047
  • Unexpected reactivity of cyclic perfluorinated iodanes with electrophiles Gruber S, Ametamey SM , Schibli R
    CHEMICAL COMMUNICATIONS 54, 8999 (2018).
    DOI: c8cc04558e
  • Diastereomerically Pure 6R- and 6S-3'-aza-2'-18F-Fluoro-5-Methyltetrahydrofolates Show Unprecedented High Uptake in Folate Receptor-positive KB Tumors Boss SD, Müller C, Siwowska K, Schmid RM, Groehn V, Schibli R, Ametamey SM
    JOURNAL OF NUCLEAR MEDICINE , (2018).
    DOI: jnumed.118.213314
  • Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells Kranzbühler B, Salemi S, Umbricht CA, Müller C, Burger IA, Sulser T, Eberli D
    PROSTATE 78, 758 (2018).
    DOI: pros.23522
  • Combining Albumin-Binding Properties and Interaction with Pemetrexed to Improve the Tissue Distribution of Radiofolates Müller C, Guzik P, Siwowska K, Cohrs S, Schmid RM, Schibli R
    MOLECULES 23, E1465 (2018).
    DOI: molecules23061465
  • Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application Müller C, Domnanich KA, Umbricht CA, van der Meulen NP
    BRITISH JOURNAL OF RADIOLOGY , (2018).
    DOI: bjr.20180074
  • Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy Umbricht CA, Benešová M, Schibli R, Müller C
    MOLECULAR PHARMACEUTICALS , (2018).
    DOI: acs.molpharmaceut.8b00152
  • Injected Human Muscle Precursor Cells Overexpressing PGC-1α Enhance Functional Muscle Regeneration after Trauma Haralampieva D, Salemi S, Betzel T, Dinulovic I, Krämer SD, Schibli R, Sulser T, Handschin C, Ametamey SM, Eberli D
    STEM CELL INTERNATIONAL 2018, 465850 (2018).
    DOI: 4658503
  • Radiosynthesis and evaluation of an 18F-labeled silicon containing exendin-4 peptide as a PET probe for imaging insulinoma Dialer LO, Jodal A, Schibli R, Ametamey SM, Béhé M
    EJNMMI RADIOPHARMACY AND CHEMISTRY 3, 1 (2018).
    DOI: s41181-017-0036-6
  • Improved Syntheses of the Mglu₅ Antagonists MMPEP and MTEP Using Sonogashira Cross-Coupling Mu B, Mu L, Schibli R, Ametamey SM, Milicevic Sephton S
    PHARMACEUTICALS (BASEL) 11, E24 (2018).
    DOI: ph11010024
  • Evaluation of 4-oxo-quinoline-based CB2 PET radioligands in R6/2 chorea huntington mouse model and human ALS spinal cord tissue Haider A, Spinelli F, Herde AM, Mu B, Keller C, Margelisch M, Weber M, Schibli R, Mu L, Ametamey SM
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 145, 746 (2018).
    DOI: j.ejmech.2017.12.097
  • Evaluation of 11C-Me-NB1 as a Potential PET Radioligand for Measuring GluN2B-Containing NMDA Receptors, Drug Occupancy, and Receptor Cross Talk Krämer SD, Betzel T, Mu L, Haider A, Herde AM, Boninsegni AK, Keller C, Szermerski M, Schibli R, Wünsch B, Ametamey SM
    JOURNAL OF NUCLEAR MEDICINE 59, 698 (2018).
    DOI: jnumed.117.200451
  • A first-in-man PET study of [18F]PSS232, a fluorinated ABP688 derivative for imaging metabotropic glutamate receptor subtype 5 Warnock G, Sommerauer M, Mu L, Pla Gonzalez G, Geistlich S, Treyer V, Schibli R, Buck A, Krämer SD, Ametamey SM
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 45, 1041 (2018).
    DOI: s00259-017-3879-x
  • Imaging of Folate Receptor Expressing Macrophages in the Rat Groove Model of Osteoarthritis: Using a New DOTA-Folate Conjugate de Visser HM, Korthagen NM, Müller C, Ramakers RM, Krijger GC, Lafeber FPJG, Beekman FJ, Mastbergen SC, Weinans H
    CARTILAGE 9, 183 (2018).
    DOI: 1947603517738073
  • Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile Benešová M, Umbricht CA, Schibli R, Müller C
    MOLECULAR PHARMACEUTICS 15, 934 (2018).
    DOI: acs.molpharmaceut.7b00877
  • Reduced 18F-Folate Conjugates as a New Class of PET Tracers for Folate Receptor Imaging Boss SD, Müller C, Siwowska K, Büchel JI, Schmid RM, Groehn V, Schibli R, Ametamey SM
    BIOCONJUGATE CHEMISTRY 29, 1119 (2018).
    DOI: acs.bioconjchem.7b00775

2017

  • Metabotropic glutamate receptor 5 binding in male patients with alcohol use disorder Akkus F, Mihov Y, Treyer V, Ametamey SM, Johayem A, Senn S, Rösner S, Buck A, Hasler G
    TRANSLATIONAL PSYCHIATRY 8, 17 (2017).
    DOI: s41398-017-0066-6
  • Imaging the glutamate receptor subtypes-Much achieved, and still much to do Gruber S, Ametamey SM
    DRUG DISCOVERY TODAY: TECHNOLOGIES 25, 27 (2017).
    DOI: j.ddtec.2017.10.006
  • Radioligands for positron emission tomography imaging of cannabinoid type 2 receptor Spinelli F, Mu L, Ametamey SM
    JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS , (2017).
    DOI: jlcr.3579
  • Cerebral mGluR5 availability contributes to elevated sleep need and behavioral adjustment after sleep deprivation Holst SC, Sousek A, Hefti K, Saberi-Moghadam S, Buck A, Ametamey SM, Scheidegger M, Franken P, Henning A, Seifritz E, Tafti M, Landolt HP
    eLIFE , e28751 (2017).
    DOI: eLife.28751
  • Novel peptide probes to assess the tensional state of fibronectin fibers in cancer Arnoldini S, Moscaroli A, Chabria M, Hilbert M, Hertig S, Schibli R, Béhé M, Vogel V
    NATURE COMMUNICATIONS 8, 1793 (2017).
    DOI: s41467-017-01846-0
  • Towards Translational ImmunoPET/MR Imaging of Invasive Pulmonary Aspergillosis: The Humanised Monoclonal Antibody JF5 Detects Aspergillus Lung Infections In Vivo Davies G, Rolle AM, Maurer A, Spycher PR, Schillinger C, Solouk-Saran D, Hasenberg M, Weski J, Fonslet J, Dubois A, Boschetti F, Denat F, Gunzer M, Eichner M, Ryder LS, Jensen M, Schibli R, Pichler BJ, Wiehr S, Thornton CR
    THERANOSTICS 7, 3398 (2017).
    DOI: thno.20919
  • Synthesis, Radiolabeling, and Characterization of Plasma Protein-Binding Ligands: Potential Tools for Modulation of the Pharmacokinetic Properties of (Radio)Pharmaceuticals Müller C, Farkas R, Borgna F, Schmid RM, Benešová M, Schibli R
    BIOCONJUGATE CHEMISTRY 28, 2372 (2017).
    DOI: acs.bioconjchem.7b00378
  • Therapeutic Radiometals Beyond 177Lu and 90Y: Production and Application of Promising α-Particle, β--Particle, and Auger Electron Emitters Müller C, van der Meulen NP, Benešová M, Schibli R
    JOURNAL OF NUCLEAR MEDICINE 58 (Suppl 2), 91S (2017).
    DOI: jnumed.116.186825
  • Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with 152Tb-DOTATOC Baum RP, Singh A, Benešová M, Vermeulen C, Gnesin S, Köster U, Johnston K, Müller D, Senftleben S, Kulkarni HR, Türler A, Schibli R, Prior JO, van der Meulen NP, Müller C
    DALTON TRANSACTION 46, 14638 (2017).
    DOI: c7dt01936j
  • Folate Receptor-Positive Gynecological Cancer Cells: In Vitro and In Vivo Characterization Siwowska K, Schmid RM, Cohrs S, Schibli R, Müller C
    PHARMACEUTICALS (BASEL) 10, E72 (2017).
    DOI: ph10030072
  • Dual, Site-Specific Modification of Antibodies by Using Solid-Phase Immobilized Microbial Transglutaminase Spycher PR, Amann CA, Wehrmüller JE, Hurwitz DR, Kreis O, Messmer D, Ritler A,3, Küchler A, Blanc A, Béhé M, Walde P, Schibli R
    CHEMBIOCHEM 18, 1923 (2017).
    DOI: cbic.201700188
  • A Short-Term Biological Indicator for Long-Term Kidney Damage after Radionuclide Therapy in Mice Pellegrini G, Siwowska K, Haller S, Antoine DJ, Schibli R, Kipar A, Müller C
    PHARMACEUTICALS (BASEL) 10, E57 (2017).
    DOI: ph10020057
  • First-in-Human PET/CT Imaging of Metastatic Neuroendocrine Neoplasms with Cyclotron-Produced 44Sc-DOTATOC: A Proof-of-Concept Study Singh A,van der Meulen NP, Müller C, Klette I, Kulkarni HR, Türler A, Schibli R, Baum RP
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS 32, 124 (2017).
    DOI: cbr.2016.2173
  • Radiolabeled 111In-FGF-2 Is Suitable for In Vitro/Ex Vivo Evaluations and In Vivo Imaging Moscaroli A, Jones G, Lühmann T, Meinel L, Wälti S, Blanc A, Fischer E, Hilbert M, Schibli R, Béhé M
    MOLECULAR PHARMACEUTICS 14, 639 (2017).
    DOI: acs.molpharmaceut.6b0091
  • Automated cGMP-compliant radiosynthesis of [18 F]-(E)-PSS232 for brain PET imaging of metabotropic glutamate receptor subtype 5 Park JY, Son J, Yun M, Ametamey SM, Chun JH
    JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS , (2017).
    DOI: jlcr.3566
  • Human Muscle Precursor Cells Overexpressing PGC-1α Enhance Early Skeletal Muscle Tissue Formation Haralampieva D, Salemi S, Dinulovic I, Sulser T, Ametamey SM, Handschin C, Eberli D
    CELL TRANSPLANTATION 26, 1103 (2017).
    DOI: 096368917X694868
  • Kinetics of lipid bilayer permeation of a series of ionisable drugs and their correlation with human transporter-independent intestinal permeability Hermann KF, Neuhaus CS, Micallef V, Wagner B, Hatibovic M, Aschmann HE, Paech F, Alvarez-Sanchez R, Krämer SD, Belli S
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 104, 150 (2017).
    DOI: j.ejps.2017.03.040
  • GABAA receptor subtypes in the mouse brain: Regional mapping and diazepam receptor occupancy by in vivo [18F]flumazenil PET Müller Herde A, Benke D, Ralvenius WT, Mu L, Schibli R, Zeilhofer HU, Krämer SD
    NEUROIMAGE 15, 279 (2017).
    DOI: j.neuroimage.2017.02.022
  • Cannabinoid receptor type 2 (CB2) as one of the candidate genes in human carotid plaque imaging: Evaluation of the novel radiotracer [11C]RS-016 targeting CB2 in atherosclerosis Meletta R, Slavik R, Mu L, Rancic Z, Borel N, Schibli R, Ametamey SM, Krämer SD, Müller Herde A
    NUCLEAR MEDICINE AND BIOLOGY 47, 31 (2017).
    DOI: j.nucmedbio.2017.01.001
  • 44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617-preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617 Umbricht CA, Benešová M, Schmid RM, Türler A, Schibli R, van der Meulen NP, Müller C
    EJNMMI RESEARCH 7, 9 (2017).
    DOI: s13550-017-0257-4
  • Metabotropic glutamate receptor 5 neuroimaging in schizophrenia Akkus F, Treyer V, Ametamey SM, Johayem A, Buck A, Hasler G
    SCHIZOPHRENIA RESEARCH 183, 95 (2017).
    DOI: j.schres.2016.11.008
  • Preclinical Comparison of Albumin-Binding Radiofolates: Impact of Linker Entities on the in Vitro and in Vivo Properties Siwowska K, Haller S, Bortoli F, Benešová M, Groehn V, Bernhardt P, Schibli R, Müller C
    MOLECULAR PHARMACEUTICS 14, 523 (2017).
    DOI: acs.molpharmaceut.6b01010
  • Methoxinine - an alternative stable amino acid substitute for oxidation-sensitive methionine in radiolabelled peptide conjugates Grob NM, Behe M, von Guggenberg E, Schibli R, Mindt TL
    JOURNAL OF PEPTIDE SCIENCE 23, 38 (2017).
    DOI: psc.2948
  • Targets and probes for non-invasive imaging of β-cells Jodal A, Schibli R, Béhé M
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 44, 712 (2017).
    DOI: s00259-016-3592-1

2016

  • 44Sc for labeling of DOTA- and NODAGA functionalized peptides: preclinical in vitro and in vivo investigations Domnanich KA, Müller C, Farkas R, Schmid RM, Ponsard B, Schibli S, Türler A, van der Meulen NP
    EJNMMI RADIOPHARMACY AND CHEMISTRY 1, 5 (2016).
    DOI: s41181-016-0013-5
  • Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics Müller C, Vermeulen C, Köster U, Johnston K, Türler A, Schibli R, van der Meulen NP
    EJNMMI RADIOPHARMACY AND CHEMISTRY 1, 5 (2016).
    DOI: s41181-016-0008-2
  • Preclinical in vivo application of (152)Tb-DOTANOC: a radiolanthanide for PET imaging Müller C, Vermeulen C, Johnston K, Köster U, Schmid R, Türler A, van der Meulen NP
    EJNMMI RESEARCH 6, 35 (2016).
    DOI: s13550-016-0189-4
  • Evaluation of the first 44Sc-labeled Affibody molecule for imaging of HER2-expressing tumors Honarvar H, Müller C, Cohrs S, Haller S, Westerlund K, Karlström AE, van der Meulen NP, Schibli R, Tolmachev V
    NUCLEAR MEDICINE AND BIOLOGY 45, 15 (2016).
    DOI: j.nucmedbio.2016.10.004
  • Production of (28)Mg by bombardment of (nat)Cl with 200MeV protons: Proof-of-concept study for a stacked LiCl target van der Meulen NP, Steyn GF, Vermeulen C, van Rooyen TJ
    APPLIED RADIATION AND ISOTOPES 115, 125 (2016).
    DOI: j.apradiso.2016.04.026
  • Enhanced sensitivity to drugs of abuse and palatable foods following maternal overnutrition Peleg-Raibstein D, Sarker G, Litwan K, Krämer SD, Ametamey SM, Schibli R, Wolfrum C
    TRANSLATIONAL PSYCHIATRY 6, e911 (2016).
    DOI: tp.2016.176
  • Synthesis and Pharmacological Evaluation of [11C]Granisetron and [18F]Fluoropalonosetron as PET Probes for 5-HT3 Receptor Imaging Mu L, Müller Herde A, Rüefli PM, Sladojevich F, Milicevic Sephton S, Krämer SD, Thompson AJ, Schibli R, Ametamey SM, Lochner M
    ACS CHEMICAL NEUROSCIENCE 7, 1552 (2016).
    DOI: acschemneuro.6b00192
  • Synthesis and Biological Evaluation of Thiophene-Based Cannabinoid Receptor Type 2 Radiotracers for PET Imaging Haider A, Müller Herde A, Slavik R, Weber M, Mugnaini C, Ligresti A, Schibli R, Mu L, Mensah Ametamey S
    FRONTIERS IN NEUROSCIENCE 10, 350 (2016).
    DOI: fnins.2016.00350
  • CD80 Is Upregulated in a Mouse Model with Shear Stress-Induced Atherosclerosis and Allows for Evaluating CD80-Targeting PET Tracers Meletta R, Steier L, Borel N, Mu L, Keller C, Chiotellis A, Russo E, Halin C, Ametamey SM, Schibli R, Krämer SD, Müller Herde A
    MOLUCULAR IMAGING and BIOLOGY Epub ahead of print, (2016).
    DOI: s11307-016-0987-0
  • Discovery of a Fluorinated 4-Oxo-Quinoline Derivative as a Potential PET Radiotracer for Imaging CB2 Receptor Slavik R, Müller Herde A, Haider A, Krämer SD, Weber M, Schibli R, Ametamey SM, Mu L
    JOURNAL OF NEUROCHEMISTRY 138, 874 (2016).
    DOI: jnc.13716
  • Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy Grzmil M, Seebacher J, Hess D, Behe M, Schibli R, Moncayo G, Frank S, Hemmings BA
    CELLULAR SIGNALLING 28, 1412 (2016).
    DOI: j.cellsig.2016.06.005
  • Non-invasive Imaging and Tracking of Engineered Human Muscle Precursor Cells for Skeletal Muscle Tissue Engineering Using Positron Emission Tomography Haralampieva D, Betzel T, Dinulovic I, Salemi S, Stoelting M, Krämer S, Schibli R, Sulser T, Handschin C, Eberli D, Ametamey SM
    JOURNAL OF NUCLEAR MEDICINE Epub ahead of print, (2016).
    DOI:
  • Synthesis, Radiolabeling, and Biological Evaluation of 5-Hydroxy-2-[(18)F]fluoroalkyl-tryptophan Analogues as Potential PET Radiotracers for Tumor Imaging Chiotellis A, Müller Herde A, Rössler SL, Brekalo A1, Gedeonova E, Mu L, Keller C, Schibli R, Krämer SD, Ametamey SM
    JOURNAL OF MEDICINAL CHEMISTRY 59, 5324 (2016).
    DOI: acs.jmedchem.6b00057
  • (64)Cu- and (68)Ga-Based PET Imaging of Folate Receptor-Positive Tumors: Development and Evaluation of an Albumin-Binding NODAGA-Folate Farkas R, Siwowska K, Ametamey SM, Schibli R, van der Meulen NP, Müller C
    MOLECULAR PHARMACEUTICS 13, 1979 (2016).
    DOI: acs.molpharmaceut.6b00143
  • Novel chemoselective (18)F-radiolabeling of thiol-containing biomolecules under mild aqueous conditions Chiotellis A, Sladojevich F, Mu L, Müller Herde A, Valverde IE, Tolmachev V, Schibli R, Ametamey SM, Mindt TL
    CHEMICAL COMMUNICATION 52, 6083 (2016).
    DOI: c6cc01982j
  • Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)Tb-folate and (177)Lu-folate Haller S, Pellegrini G, Vermeulen C, van der Meulen NP, Köster U, Bernhardt P, Schibli R, Müller C
    EJNMMI RESEARCH 1, 13 (2016).
    DOI: s13550-016-0171-1
  • ImmunoPET/MR imaging allows specific detection of Aspergillus fumigatus lung infection in vivo Rolle AM, Hasenberg M, Thornton CR, Solouk-Saran D, Männ L, Weski J, Maurer A, Fischer E, Spycher PR, Schibli R, Boschetti F, Stegemann-Koniszewski S, Bruder D, Severin GW, Autenrieth SE, Krappmann S, Davies G, Pichler BJ, Gunzer M, Wiehr S
    PNAS 113, E1026 (2016).
    DOI: pnas.1518836113
  • Imaging quality of (44)Sc in comparison with five other PET radionuclides using Derenzo phantoms and preclinical PET Bunka M, Müller C, Vermeulen C, Haller S, Türler A, Schibli R, van der Meulen NP
    APPLIED RADIATION AND ISOTOPES 110, 129 (2016).
    DOI: j.apradiso.2016.01.006
  • Preclinical imaging of the co-stimulatory molecules CD80 and CD86 with indium-111-labeled belatacept in atherosclerosis Meletta R, Müller Herde A, Dennler P, Fischer E, Schibli R, Krämer SD
    EJNMMI RESEARCH 6, 1 (2016).
    DOI: s13550-015-0157-4
  • Comparative Studies of Three Pairs of α- and γ-Conjugated Folic Acid Derivatives Labeled with Fluorine-18 Boss SD, Betzel T, Müller C, Fischer CR, Haller S, Reber J, Groehn V, Schibli R, Ametamey SM
    BIOCONJUGATE CHEMISTRY 27, 74 (2016).
    DOI: acs.bioconjchem.5b00644

2015

  • Ex vivo differential phase contrast and magnetic resonance imaging for characterization of human carotid atherosclerotic plaque Meletta R, Borel N, Stolzmann P, Astolfo A, Klohs J, Stampanoni M, Rudin M, Schibli R, Krämer SD, Müller Herde A
    THE INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING 31, 1425 (2015).
    DOI: s10554-015-0706-y
  • Folate receptor-targeted radionuclide therapy: preclinical investigation of anti-tumor effects and potential radionephropathy Haller S, Reber J, Brandt S, Bernhardt P, Groehn V, Schibli R, Müller C
    NUCLEAR MEDICINE AND BIOLOGY 42, 770 (2015).
    DOI: j.nucmedbio.2015.06.006
  • Cyclotron production of (44)Sc: From bench to bedside van der Meulen NP, Bunka M, Domnanich KA, Müller C, Haller S, Vermeulen C, Türler A, Schibli R
    NUCLEAR MEDICINE AND BIOLOGY 42, 745 (2015).
    DOI: j.nucmedbio.2015.05.00
  • Longitudinal in vivo evaluation of bone regeneration by combined measurement of multi-pinhole SPECT and micro-CT for tissue engineering Lienemann PS, Metzger S, Kiveliö AS, Blanc A, Papageorgiou P, Astolfo A, Pinzer BR, Cinelli P, Weber FE, Schibli R, Béhé M, Ehrbar M
    SCIENTIFIC REPORTS 5, 10238 (2015).
    DOI: srep10238 Erratum DOI: srep12391
  • Discovery of a high affinity and selective pyridine analog as a potential positron emission tomography imaging agent for cannabinoid type 2 receptor Slavik R, Grether U, Müller Herde A, Gobbi L, Fingerle J, Ullmer C, Krämer SD, Schibli R, Mu L, Ametamey SM
    JOURNAL OF MEDICINAL CHEMISTRY 58, 4266 (2015).
    DOI: acs.jmedchem.5b00283
  • Evaluation of a Novel Tc-99m Labelled Vitamin B12 Derivative for Targeting Escherichia coli and Staphylococcus aureus In Vitro and in an Experimental Foreign-Body Infection Model Baldoni D, Waibel R, Bläuenstein P, Galli F, Iodice V, Signore A, Schibli R, Trampuz A
    MOLECULAR IMAGING AND BIOLOGY 10, e0123443 (2015).
    DOI: s11307-015-0832-x
  • Evaluation of ¹¹¹in-labelled exendin-4 derivatives containing different meprin β-specific cleavable linkers Jodal A, Pape F, Becker-Pauly C, Maas O, Schibli R, Béhé M
    PLOS ONE 10, e0123443 (2015).
    DOI: journal.pone.0123443
  • Regional cerebral blood flow estimated by early PiB uptake is reduced in mild cognitive impairment and associated with age in an amyloid-dependent manner Gietl AF, Warnock G, Riese F, Kälin AM, Saake A, Gruber E, Leh SE, Unschuld PG, Kuhn FP, Burger C, Mu L, Seifert B, Nitsch RM, Schibli R, Ametamey SM, Buck A, Hock C
    NEUROBIOLOGY OF AGING 36, 1619 (2015).
    DOI: j.neurobiolaging.2014.12.036
  • Microbial transglutaminase and c-myc-tag: a strong couple for the functionalization of antibody-like protein scaffolds from discovery platforms Dennler P, Bailey LK, Spycher PR, Schibli R, Fischer E
    CHEMBIOCHEM 16, 861 (2015).
    DOI: cbic.201500009
  • Dosimetry and first clinical evaluation of the new 18F-radiolabeled bombesin analogue BAY 864367 in patients with prostate cancer Sah BR, Burger IA, Schibli R, Friebe M, Dinkelborg L, Graham K, Borkowski S, Bacher-Stier C, Valencia R, Srinivasan A, Hany TF, Mu L, Wild PJ, Schaefer NG
    JOURNAL OF NUCLEAR MEDICINE 56, 372 (2015).
    DOI: jnumed.114.147116
  • Synthesis and pharmacological evaluation of ¹¹C-labeled piperazine derivative as a PET probe for sigma-2 receptor imaging Selivanova SV, Toscano A, Abate C, Berardi F, Müller A, Krämer SD, Schibli R, Ametamey SM
    NUCLEAR MEDICINE AND BIOLOGY 42, 399 (2015).
    DOI: j.nucmedbio.2014.12.018
  • Evaluation of the radiolabeled boronic acid-based FAP inhibitor MIP-1232 for atherosclerotic plaque imaging Meletta R, Müller Herde A, Chiotellis A, Isa M, Rancic Z, Borel N, Ametamey SM, Krämer SD, Schibli R
    MOLUCULES 20, 2081 (2015).
    DOI: molecules20022081
  • Investigation of the chick embryo as a potential alternative to the mouse for evaluation of radiopharmaceuticals Haller S, Ametamey SM, Schibli R, Müller C
    NUCLEAR MEDICINE AND BIOLOGY 42, 226 (2015).
    DOI: j.nucmedbio.2014.10.010
  • Quantitative positron emission tomography of mGluR5 in rat brain with [(18) F]PSS232 at minimal invasiveness and reduced model complexity Müller Herde A, Keller C, Milicevic Sephton S, Mu L, Schibli R, Ametamey SM, Krämer SD
    JOURNAL OF NEUROCHEMISTRY 133, 330 (2015).
    DOI: jnc.13001
  • Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models Lhospice F, Delphine B, Belmant C, Patrick D, Aristeidis C, Fischer E, Laurent G, Bonnafous C, Viaud N, Represa A, Boëdec A, Rispaud Blanc H, Sapet M, Delcambre C, Ingoure S, Savard Chambard S, Schneider N, Paturel C, Schibli R, Romagne F
    MOLECULAR PHARMACEUTICS 12, 1863 (2015).
    DOI: mp500666j
  • Association of Long-Term Nicotine Abstinence with Normal Metabotropic Glutamate Receptor-5 Binding Akkus F, Treyer V, Johayem A, Ametamey SM, Mancilla BG, Sovago J, Buck A, Hasler G
    BIOLOGYCAL PSYCHATRY , (2015).
    DOI: 10.1016/j.biopsych.2015.02.027
  • Synthesis, radiolabeling and evaluation of novel 4-oxo-quinoline derivatives as PET tracers for imaging cannabinoid type 2 receptor Slavik R, Herde AM1, Bieri D, Weber M, Schibli R, Krämer SD, Ametamey SM, Mu L
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 92, 554 (2015).
    DOI: j.ejmech.2015.01.028
  • Folate Receptor-Targeted Multimodality Imaging of Ovarian Cancer in a Novel Syngeneic Mouse Model Ocak M, Gillman AG, Bresee J, Zhang L, Vlad AM, Müller C, Schibli R, Edwards WB, Anderson CJ, Gach HM
    MOLECULAR PHARMACEUTICS 12, 542 (2015).
    DOI: mp500628g
  • Self-assembled gold coating enhances X-ray imaging of alginate microcapsules Qie F, Astolfo A, Wickramaratna M, Behe M, Evans MD, Hughes TC, Hao X, Tan T
    NANOSCALE 7, 2480 (2015).
    DOI: c4nr06692h
  • Excitation functions of natZr + p nuclear processes up to 70 MeV: New measurements and compilation Szelecsényi F, Steyn GF, Kovács Z, Vermeulen C, Nagatsu K, Zhang MR, Suzuki K
    NUCLEAR INSTRUMENTS AND METHODS IN PHYSICS RESEARCH B 343, 173 (2015).
    DOI: j.nimb.2014.11.081
  • Preclinical evaluation and test-retest studies of [(18)F]PSS232, a novel radioligand for targeting metabotropic glutamate receptor 5 (mGlu5) Sephton SM, Herde AM, Mu L, Keller C, Rüdisühli S, Auberson Y, Schibli R, Krämer SD, Ametamey SM
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 42, 128 (2015).
    DOI: s00259-014-2883-7

Contact ETH
Prof. Dr. Roger Schibli
Swiss Federal Institute of Technology Zurich
Radiopharmaceutical Sciences
ETH Zurich